Literature DB >> 2831338

A new 21-aminosteroid antioxidant lacking glucocorticoid activity stimulates adrenocorticotropin secretion and blocks arachidonic acid release from mouse pituitary tumor (AtT-20) cells.

J M Braughler1, R L Chase, G L Neff, P A Yonkers, J S Day, E D Hall, V H Sethy, R A Lahti.   

Abstract

The compound U74006F (21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16 alpha-methyl- pregna-1,4,9(11)-triene-3,20-dione) is one of a novel series of 21-aminosteroids that are potent inhibitors of iron-dependent lipid peroxidation. Chronic (4-6 days) dosing of mice or rats with high doses of U74006F (30-200 mg/kg/day) has indicated that the compound is devoid of both glucocorticoid and mineralocorticoid activity. Although the compound is not a glucocorticoid antagonist, it markedly stimulated secretion of adrenocorticotropin by the murine pituitary tumor (AtT-20) cell. The enhanced secretion of adrenocorticotropin was not associated with an increased incorporation of [3H]thymidine or [14C]leucine into DNA or protein, respectively. Although not a glucocorticoid, U74006F also blocked the release of [14C]arachidonic acid from AtT-20 cells damaged by either Fe++ or the metabolic poison, iodoacetate. U74006F represents a novel class of antioxidant which displays cytoprotective activity and may uniquely affect cell growth or function in culture systems.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831338

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  Antioxidant therapies for acute spinal cord injury.

Authors:  Edward D Hall
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 2.  Neuroprotection and acute spinal cord injury: a reappraisal.

Authors:  Edward D Hall; Joe E Springer
Journal:  NeuroRx       Date:  2004-01

Review 3.  Review of progress in sterol oxidations: 1987-1995.

Authors:  L L Smith
Journal:  Lipids       Date:  1996-05       Impact factor: 1.880

4.  Comparison of various lazaroid compounds for protection against ischemic liver injury.

Authors:  N Ishizaki; Y Zhu; S Zhang; A Nemoto; Y Kobayashi; V M Subbotin; R G Lee; T E Starzl; S Todo
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

Review 5.  Mitochondrial-Based Therapeutics for the Treatment of Spinal Cord Injury: Mitochondrial Biogenesis as a Potential Pharmacological Target.

Authors:  Natalie E Scholpa; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2017-09-21       Impact factor: 4.030

6.  The effects of the pretreatment of intravenous high dose methylprednisolone on Na(+)-K(+)/Mg(+2) ATPase and lipid peroxidation and early ultrastructural findings following middle cerebral artery occlusion in the rat.

Authors:  F Ildan; S Polat; A I Göcer; A Oner; T Isbir; U O Mete; M Kaya; A Karadayi
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

7.  Attenuation of acute inflammatory effects of silica in rat lung by 21-aminosteroid, U74389G.

Authors:  J M Antonini; K van Dyke; M DiMatteo; M J Reasor
Journal:  Inflammation       Date:  1995-02       Impact factor: 4.092

8.  Lazaroids inhibit proliferation of cultured human astrocytoma cells.

Authors:  P Arora; Y S Lee; T C Origitano; R D Wurster
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

9.  Retinal toxicity of intravitreal lazaroid (21-aminosteroid U75412E).

Authors:  S A Cruz; M Karaçorlu; G A Peyman
Journal:  Int Ophthalmol       Date:  1992-05       Impact factor: 2.031

10.  Improved survival and reversal of endothelial dysfunction by the 21-aminosteroid, U-74389G in splanchnic ischaemia-reperfusion injury in the rat.

Authors:  F Squadrito; D Altavilla; L Ammendolia; G Squadrito; G M Campo; A Sperandeo; P Canale; M Ioculano; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.